Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas
Authors:
- 1 August 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (5) , 705-714
Abstract
Escape from immune detection favors both tumor survival and progression, and new approaches to circumvent this are essential to combat cancers. Nonvirulent, tumortropic bacteria, such as Salmonella typhimurium, can unmask a tumor by transforming it into a site of inflammation; however, the nonspecific invasiveness of Salmonella leads to off-target effects diluting its therapeutic efficacy and making its use in human patients inherently risky. Here, we demonstrate that Salmonella tumor specificity can be significantly improved via a surface-expressed single-domain antibody directed to a tumor-associated antigen (CD20). Antibody-dependent bacterial targeting specifies the infection of CD20+ lymphoma cells in vitro and in vivo, while significantly diminishing nonspecific cell invasion. Indeed, CD20-targeted Salmonella was less generally invasive, even in organs that normally serve as physiological reservoirs. Furthermore, tumor-specific Salmonella engineered to carry the herpes simplex virus thymidine kinase prodrug-converting enzyme effectively treats human lymphoma xenografts when coadministered intratumorally or intravenously with ganciclovir in mice lacking a functional adaptive immune system. Therefore, tumor-targeted Salmonella could prove effective even in those patients displaying a debilitated immune system, which is often the case with late-stage cancers. Altogether, antibody-displaying Salmonella vectors can mediate a tumor-specific response and rejection with few detectable adverse effects while specifically delivering cytotoxic payloads.Keywords
This publication has 34 references indexed in Scilit:
- Antibody-Based Immunotherapy of CancerCell, 2012
- Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logicNucleic Acids Research, 2011
- Enhancement of Cancer Vaccine Therapy by Systemic Delivery of a Tumor-TargetingSalmonella-Based STAT3 shRNA Suppresses the Growth of Established Melanoma TumorsCancer Research, 2011
- Bacteria-Induced Gap Junctions in Tumors Favor Antigen Cross-Presentation and Antitumor ImmunityScience Translational Medicine, 2010
- Immunological applications of single-domain llama recombinant antibodies isolated from a naïve libraryProtein Engineering, Design and Selection, 2009
- Intra‐tumoral Salmonella typhimurium induces a systemic anti‐tumor immune response that is directed by low‐dose radiation to treat distal diseaseEuropean Journal of Immunology, 2008
- Entry Route of Salmonella typhimurium Directs the Type of Induced Immune ResponseImmunity, 2007
- In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccinesJournal of Clinical Investigation, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Efficient tumor targeting by single‐domain antibody fragments of camelsInternational Journal of Cancer, 2002